Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 258

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 258
---
 (the same effect on cash and cash equivalents considering the cash inflow from said financing). (6)Under the terms of the Business Combination Agreement, after December31, 2024 but prior to the closing of said business combination: (a)The Parent will contribute its financial receivable, including accrued interests as of the contribution date, to its subsidiary, OmnigenicsAI. This receivable originated from a loan disbursed to OmnigenicsAI on August 5, 2024 (original financing amount of $47,693) and the contribution will be made without issuing new shares; and (b)Loans provided by the Parent to Heritas Argentina (originally granted on January6, 2022, and subsequently amended on January1, 2024, and January10, 2024) amount to a total capital financing of $647,426. This outstanding debt, plus accrued interest as of the closing date, will be contributed by Parent to OmnigenicsAI, without the issuance of new shares, in accordance with Cayman Islands law. Subsequently, OmnigenicsAI will contribute its outstanding debt to Heritas Argentina as an irrevocable in -kindcontribution to Heritas Argentina. As a result of this contribution, and in accordance with Argentinean law, Heritas Argentina will issue new shares corresponding to the value of the contributed debt. These newly issued shares will be allocated to OmnigenicsAI, which will remain the sole (100%) shareholder of Heritas Argentina following the transaction. There will be no change in ownership, and the capital increase will solely reflect the conversion of the outstanding debt into equity. The effects of these in -kindcontributions on the Pro Forma Statement of Financial Position are as as of December31, 2024 follows: •Decrease in current and non -currentloans by $48,950 and $705,983, respectively, considering the book value of these financings disclosed in the interim condensed combined financial statements of OmnigenicsAI as of December31, 2024. •Increase of $754,933 in the Accumulated deficit as a result of these in -kindcontributions from the Parent to OmnigenicsAI, as these do not involve the issuance of new shares of OmnigenicsAI. 112

Share Capital The composition of the share capital after giving pro forma effect to the Business Combination and in the different scenarios described are disclosed below (considering par value of $0.0001 per share):

|                                                |     |